



Evofem Biosciences Honors World Contraception Day

SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater.

Evofem's mission has always centered on challenging the status quo in women's health — offering groundbreaking choices where few exist and leading conversations others avoid. With products like **PHEXXI® (lactic acid, citric acid, and potassium bitartrate)**, the first and only hormone-free, on-demand contraceptive vaginal gel, and **SOLOSEC® (secnidazole) 2g oral granules**, a single-dose oral treatment for bacterial vaginosis and trichomoniasis, Evofem is working to ensure women have more tools to safeguard their reproductive and sexual health.

"World Contraception Day is about making sure every person has access to safe, effective, and affordable choices," said Sandra Pelletier, CEO of Evofem Biosciences. "Let's be honest – most women do not have sex every day. They deserve a contraceptive option that enables them to have sex on demand and PHEXXI makes this possible. We are proud to offer this non-hormonal innovative solution to the women who have suffered side effects from synthetic hormones in birth control; cancer thrivers; breast feeding mothers; and women who simply do not want to 'over-medicate' themselves with hormonal contraception."

In addition to commercializing science-backed, FDA-approved products, Evofem is committed to awareness and education campaigns that confront stigma directly. The Company's international "Say Vagina" initiative has reached millions by challenging censorship, dismantling shame surrounding female anatomy, and improving health education. Through this campaign, Evofem is turning awareness into action.

As the Company looks ahead, Evofem remains dedicated to breaking barriers, expanding global access, and

ensuring that women's health continues to receive the investment and innovation it deserves. On World Contraception Day, Evofem reaffirms its vision: a world where reproductive health options are celebrated, supported, and accessible to all.

About Evofem Biosciences

Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information.

SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Connect With Us

Media

Media@evofem.com

Investors and Potential Partners

Amy Raskopf, Chief Business Development Officer

Evofem Biosciences, Inc.

araskopf@evofem.com

(917) 673-5775

Join the Dialogue

LinkedIn

[@evofem + @saundrapelletier](#)

TikTok

[@phexxi + @saundrapelletier](#)

Instagram [@evofem, @phexxi + @saundrapelletier](#)

X [@evofem + @SaundraCEO](#)

Facebook [@evofem + @phexxi](#)

SOURCE Evofem Biosciences, Inc.